A Study of Albuferon With Ribavirin in Interferon Treatment Experienced Subjects With Chronic Hepatitis C

Completed · Phase 2

Conditions studied: Hepatitis C

In brief

This is a Phase 2, multi-center, randomized, open-label study to evaluate the safety, tolerability, and efficacy of Albuferon in subjects with hepatitis C (HEP C) who failed to respond to previous interferon alfa therapy.

Key facts

Study ID

NCT00097435

Run by

Human Genome Sciences Inc.

People needed

115

Starts

2004-10-01

Expected to finish

2007-08-01

Last updated by the study team

2013-08-02

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Mayo Clinic — Phoenix, Arizona, United States
• University of Florida CRC — Gainesville, Florida, United States
• University of Florida at Jacksonville — Jacksonville, Florida, United States
• Mayo Clinic Jacksonville — Jacksonville, Florida, United States
• Johns Hopkins University — Baltimore, Maryland, United States
• Mayo Clinic Rochester — Rochester, Minnesota, United States
• Duke University — Durham, North Carolina, United States
• Metropolitan Research — Fairfax, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.